TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8185094
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula (at 10 L/min)
Study: 8185094
Drug: Oxygen supply
Normalized name: Oxygen Supply Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen supply tubing (at 15 L/min)
Study: 23834410
Drug: Propofol-remifentanil (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-remifentanil (group PR) - 56 μg/kg/min of propofol and 0.06 μg/kg/min of remifentanil
Study: 18492366
Drug: Short GnRH
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short GnRH agonist protocol with buserelin nasal sprays from day 2 and recombinant FSH from day 5
Study: 18492366
Drug: Long GnRH
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long GnRH agonist protocol with buserelin from previous mid-luteal phase and recombinant FSH after down-regulation
Study: 8919897
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of nitric oxide (NO) at a concentration of 30 ppm
Study: 1882901
Drug: Sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate suspension (1 g q.i.d. for a maximum of 3 weeks)
Study: 7051805
Drug: CFP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFP with radiation therapy
Study: 29140831
Drug: HBOC-201 (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC-201 (13 g Hb/dL)
Study: 29140831
Drug: Packed red
Normalized name: Packed red blood cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packed red blood cells (pRBCs) (24 g Hb/dL)
Study: 29140831
Drug: PolyHeme (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PolyHeme (10 g Hb/dL)
Study: 15134988
Drug: Apomorphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine 2 mg
Study: 11915639
Drug: Topical analgesics
Normalized name: ANALGESIC TOP GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesics or systemic pain medications
Study: 9517578
Drug: Salbutamol combined
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol combined with flunisolide (1 mg every 10 min for 3 hours)
Study: 31465093
Drug: Fulvestrant plus
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant plus daily vistusertib
Study: 24267513
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - single dose of 2 grams
Study: 21282444
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of solithromycin (50 to 1,600 mg)
Study: 21282444
Drug: Seven oral
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven oral daily doses of solithromycin (200 to 600 mg)
Study: 21282444
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of solithromycin (400 mg) with food
Study: 21282444
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose regimens of solithromycin
Study: 19815268
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 20 mg per day (n=243)
Study: 17187417
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg daily for 3 months
Study: 9779681
Drug: Rebox stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebox stimulation applied daily for 3 days using a negatively charged probe electrode, at pulse duration of 100 microsec, amplitude of 160 microamp, and frequency of 3000 Hz.
Study: 7827943
Drug: 10.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 g wheat fibre (Trifyba) daily for 12 weeks
Study: 7827943
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml lactulose daily for 12 weeks
Study: 3335948
Drug: Intermittent regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent regimen (60 mg/m2/day for 4 weeks, followed by 40 mg/m2/day on 3 days a week for 4 weeks)
Study: 3335948
Drug: Long-term tapering
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term tapering regimen (60 mg/m2/day for 4 weeks, followed by the same dose on alternate days for 4 weeks and tapering by 10 mg/m2 on alternate days every 4 weeks for 5 months)
Study: 26077412
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg/week) or Adalimumab (40 mg/2 week) subcutaneously for 1 year
Study: 21605608
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg kg⁻¹ BM
Study: 19598210
Drug: Heavy alcohol
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy alcohol consumption (>=50 g of alcohol daily)
Study: 19598210
Drug: Regular heavy
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular heavy drinking (>=4 drinks daily on >=5 days per week)
Study: 19598210
Drug: Drinking >=50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking >=50 g of alcohol daily in the finasteride arm
Study: 16452559
Drug: Risperidone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (3 mg daily for 8 weeks)
Study: 8652810
Drug: Intensive timing
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive timing induction therapy (4-day cycle of five active chemotherapeutic agents, second cycle 10 days after first cycle)
Study: 8652810
Drug: Standard timing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard timing induction therapy (4-day cycle of five active chemotherapeutic agents, second cycle 14 days or later after first cycle)
Study: 6202993
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy (twice a week for 24 weeks)
Study: 30487976
Drug: MOVEdiabetes intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MOVEdiabetes intervention (personalized consultations by dietitians, pedometers, monthly WhatsApp messages)
Study: 28534446
Drug: Experimental-High (EXP-High)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental-High (EXP-High) diet with 1000 mg n-3 fatty acids per serving
Study: 23899653
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic supplement
Study: 10426331
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide tablets (800 to 1,200 mg/day)
Study: 7500451
Drug: Continuous bladder
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bladder irrigation with 50 mg/l amphotericin B infused during 24 hours for 2 days
Study: 7500451
Drug: Intermittent bladder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bladder irrigations of 10 mg/100 ml amphotericin B in 1 day
Study: 2104135
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (A/Cl) for 10 days
Study: 2104135
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (A/Cl) for 3 days
Study: 2104135
Drug: Trimethoprim (TMP)
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim (TMP) as a single dose
Study: 6105556
Drug: No surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surgery (medical treatment)
Study: 31836291
Drug: Intraperitoneal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal lavage with 50 mL of 0.2% bupivacaine
Study: 28353221
Drug: PEG-IFN-containing treatment
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN-containing treatment
Study: 25886874
Drug: etoricoxib 10/30/60
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 10/30/60 mg
Study: 23536466
Drug: L-protocol (lengthening
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-protocol (lengthening exercises)
Study: 19185400
Drug: Calcium (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1,200 mg) and vitamin D(3) (800 IU) supplementation
Study: 15355651
Drug: Brachy-chemotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachy-chemotherapy group (n = 18)
Study: 11493740
Drug: Low-molecular-weight HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight HES preparation (6% HES, MW 70,000)
Study: 11493740
Drug: Medium-molecular-weight HES
Normalized name: chitosan medium molecular weight (200-800 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-molecular-weight HES preparation (6% HES, MW 200,000/0.5)
Study: 11493740
Drug: High-molecular-weight HES
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-molecular-weight HES preparation (6% HES, MW 450,000/0.7)
Study: 9615959
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy focusing on respiration, loudness, articulation, prosody, and intonation
Study: 9093728
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of oral 5-HT3 antagonists (ondansetron 8 mg b.i.d. or dolasetron 200 mg daily) plus dexamethasone 8 mg p.o. daily
Study: 2202553
Drug: 2.5% percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% percutaneous niflumic acid gel applied 3-times daily for 7 days
Study: 2202553
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied 3-times daily for 7 days
Study: 23770110
Drug: Self-management training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management training sessions with individualized action plans for COPD and comorbidities, linked to daily symptom diaries for 12 months.
Study: 21917304
Drug: Tamsulosin oral
Normalized name: tamsulosin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin oral controlled absorption system 0.4 mg/d for 1 month
Study: 21917304
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical care (corticosteroids and analgesics)
Study: 8908377
Drug: DNA-recombinant insulin
Normalized name: Insulin Glulisine (recombinant DNA origin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA-recombinant insulin
Study: 31915175
Drug: Early integration
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early integration of palliative care (EIPC) on a monthly basis
Study: 28943117
Drug: 0.4 mL
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mL of 14% benzocaine plus 0.2% benzocaine
Study: 21555333
Drug: Alcohol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (mean breath alcohol concentration = 68 mg/dL)
Study: 21555333
Drug: No-alcohol control
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No-alcohol control (0 mg/dL)
Study: 17894701
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream (1%)
Study: 27854116
Drug: 100% orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% orange juice with vitamin C 70 mg daily (G2)
Study: 31239304
Drug: Albuterol inhaled
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol inhaled with gas flow of 50 L/min
Study: 31239304
Drug: Albuterol inhaled
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol inhaled with GF:IF=1.0
Study: 31239304
Drug: Albuterol inhaled
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol inhaled with GF:IF=0.5
Study: 31239304
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL saline inhaled before albuterol doses
Study: 28285649
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) treatment for 12 weeks
Study: 25956370
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) and hMG administered simultaneously
Study: 21155616
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg/Lisinopril 10 mg
Study: 10792142
Drug: 1.0 microgram.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 microgram.kg‐1 intravenous fentanyl
Study: 9497468
Drug: Gas tamponade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gas tamponade with autologous platelet concentrate (16% C3F8 gas + 0.1 ml autologous platelet concentrate)
Study: 7686981
Drug: Leuprolide (luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (luteinizing hormone-releasing hormone agonist) given as an injection every 28 days for 24 weeks
Study: 7539852
Drug: Leuprolide (luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (luteinizing hormone-releasing hormone agonist)
Study: 27814472
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 μg once a day)
Study: 17570513
Drug: Fludarabine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m² for 6 days and oral busulfan 4 mg/kg/day for 2 days
Study: 16088264
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (autogenic training +/− pill placebo)
Study: 12187208
Drug: Monthly leuprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly leuprolide acetate (7.5 mg)
Study: 12187208
Drug: 3-month leuprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month leuprolide acetate (22.5 mg)
Study: 10442361
Drug: Oxaliplatin and
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin and UFT/oral calcium folinate
Study: 10442361
Drug: UFT/oral calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/oral calcium folinate
Study: 2132171
Drug: Ketanserin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (0.1 mg/min for 24 h)
Study: 786666
Drug: Azathioprine (AZ)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZ) 1.5 ‐ 2.0 mg/kg/day
Study: 16562817
Drug: Lean pork
Normalized name: Pork
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean pork (150 g per day)
Study: 16562817
Drug: Veal (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veal (150 g per day)
Study: 12679825
Drug: Milk fermented
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fermented with yoghurt cultures and L. casei DN‐114001 for 3 weeks
Study: 10980510
Drug: multiparticulate capsule
Normalized name: Microparticulate beta-(1,3)(1,6) glucan from saccharomyces cerevisiae
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiparticulate capsule (V)
Study: 9315418
Drug: Allendale-N9 film
Normalized name: (.alpha.3,.alpha.6,.alpha.9-tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-.kappa.n3,.kappa.n6,.kappa.n9,.kappa.n15,.kappa.o3,.kappa.o6,.kappa.o9)gadolinium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allendale-N9 film containing 100 mg N-9
Study: 9315418
Drug: Allendale-N9 film
Normalized name: (.alpha.3,.alpha.6,.alpha.9-tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-.kappa.n3,.kappa.n6,.kappa.n9,.kappa.n15,.kappa.o3,.kappa.o6,.kappa.o9)gadolinium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allendale-N9 film containing 130 mg N-9
Study: 9315418
Drug: VCF containing
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCF containing 70 mg N-9
Study: 26906148
Drug: Exercise Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Training (ET) on a cycle ergometer, performed daily at 50%-60% of maximal exercise capacity for 12 months.
Study: 22327039
Drug: Oral CR
Normalized name: Oral Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CR oxycodone 10 mg/q12h plus IV paracetamol 1g/q6h
Study: 22327039
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with continuous infusion of levobupivacaine 0.125% and sufentanil 0.7 mcg/mL at 7 mL/h
Study: 20231783
Drug: CONV (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONV (conventional treatment)
Study: 18042917
Drug: GIK infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIK infusion therapy
Study: 16518521
Drug: Propionylcarnitine (PLC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionylcarnitine (PLC) 600 mg as a single bolus followed by 1 mg/kg/min for 60 minutes
Study: 2863674
Drug: Chloramphenicol alone
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol alone by intramuscular injection
Study: 2863674
Drug: Chloramphenicol plus
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol plus penicillin by intravenous injection
Study: 31504417
Drug: Canakinumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (50 mg)
Study: 31504417
Drug: Canakinumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (150 mg)
Study: 31504417
Drug: Canakinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (300 mg)
Study: 31504417
Drug: Canakinumab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (any dose)
Study: 31504417
Drug: IL-18 and
Normalized name: Bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-18 and IL-6 (baseline and on-treatment analyses)
Study: 19066278
Drug: Single-drug taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug taxane
Study: 19066278
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anthracyclines with taxane
Study: 19066278
Drug: Taxane-based combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane-based combination with capecitabine or gemcitabine
Study: 19066278
Drug: Molecular targeted
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular targeted treatments
Study: 12592331
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP) 900-600 mg/m(2) orally
Study: 12592331
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose prednisolone 60 mg/m(2)/day orally
Study: 12592331
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP) in high-risk subgroup
Study: 12592331
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP) in high-risk subgroup aged </=2 or >/=10 years
Study: 12592331
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP) in high-risk subgroup with WBC count >/=50 x 10(9)/l
Study: 10229456
Drug: Group communication
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group communication treatment (5 hours weekly for 4 months)
Study: 10229456
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (support, performance, or movement groups)
Study: 31556095
Drug: milrinone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: milrinone (0.4 and 0.8 µg/kg/min, n = 16)
Study: 31556095
Drug: levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: levosimendan (0.1 and 0.2 µg/kg/min, n = 15)
Study: 30145660
Drug: Coronectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronectomy with adjunctive guided bone regeneration (GBR)
Study: 24980988
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg QW plus topical agent as needed
Study: 24980988
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Etanercept 50 mg BIW and Etanercept 50 mg QW plus topical agent)
Study: 21871624
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg once daily
Study: 15097153
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) 0.1 mg/kg daily (DD)
Study: 15097153
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) 0.1 mg/kg alternate days (AD)
Study: 10696916
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (IFNbeta-1a) treatment for 6 months
Study: 9350882
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral vitamin A supplementation
Study: 8223076
Drug: Lactogest (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactogest (4 capsules, approx 6000 IU)
Study: 8223076
Drug: DairyEase (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DairyEase (2 tablets, approx 6000 IU)